Effectiveness of neoadjuvant chemotherapy with FOLFOX7 in advanced gastric cancer
ZHANG Li1,LI Xiangyang1,LU Xiang1,ZHANG Qing2
1.First Department of Surgery; Shaanxi Provincial Corps Hospital of Chinese People’s Armed Police Forces, Xi’an 710054, China. 2. Institute of Liver Transplantation, General Hospital of Chinese People’s Armed Police Force, Beijing 100039, China
Abstract：Objective To evaluate the efficacy and toxicity of neoadjuvant chemotherapy with FOLFOX7 in the treatment of advanced gastric cancer. Methods Sixty-six patients with advanced gastric cancer were enrolled and were randomized to groups treated with or without neoadjuvant chemotherapy before operation (n=33/group). Preoperative chemotherapy with two cycles of FOLFOX7 were administered. The response in the primary tumor, resection rate and the chemotherapy toxicity were observed after neoadjuvant chemotherapy with FOLFOX7. Results The overall resection rate and radical resection rate in the operation with neoadjuvant chemotherapy group (93.9% and 57.6％) were higher than those in the operation without neoadjuvant chemotherapy group (78.8％and 36.4％). There were significant differences in the overall resection rate and radical resection rate between the two groups (χ2=3.911，P=0.048 and χ2=4.234，P=0.0394 ), while no significant change in complication incidence rate between the two groups. Histopathogical responses were evaluated as mild，moderate and marked in 3，4 and l cases, respectively．Conclusions FOLFOX7 is an effective and well-tolerated medicament as neoadjvant chemotherapy for the patients with advanced gastric cancer.
2012, Vol. 23 
